Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 12:17PM ET
35.24
Dollar change
+0.09
Percentage change
0.26
%
IndexRUT P/E- EPS (ttm)-5.03 Insider Own24.90% Shs Outstand47.37M Perf Week0.77%
Market Cap1.67B Forward P/E- EPS next Y-4.30 Insider Trans0.00% Shs Float35.59M Perf Month-4.76%
Income-241.36M PEG- EPS next Q-1.01 Inst Own80.37% Short Float4.50% Perf Quarter2.29%
Sales1.80M P/S927.79 EPS this Y19.43% Inst Trans8.06% Short Ratio2.07 Perf Half Y76.91%
Book/sh0.92 P/B38.37 EPS next Y-4.24% ROA-80.62% Short Interest1.60M Perf Year85.08%
Cash/sh5.86 P/C6.01 EPS next 5Y- ROE-475.31% 52W Range14.31 - 39.79 Perf YTD-7.26%
Dividend Est.- P/FCF- EPS past 5Y-43.13% ROI-95.94% 52W High-11.44% Beta2.92
Dividend TTM- Quick Ratio5.25 Sales past 5Y-16.05% Gross Margin-14.17% 52W Low146.35% ATR (14)0.62
Dividend Ex-Date- Current Ratio5.25 EPS Y/Y TTM-39.09% Oper. Margin-12178.94% RSI (14)43.81 Volatility1.03% 1.73%
Employees172 Debt/Eq4.83 Sales Y/Y TTM-17.36% Profit Margin-13408.94% Recom3.00 Target Price35.50
Option/ShortYes / Yes LT Debt/Eq4.78 EPS Q/Q-83.20% Payout- Rel Volume0.15 Prev Close35.15
Sales Surprise3168.00% EPS Surprise-66.88% Sales Q/Q496.35% EarningsFeb 28 BMO Avg Volume772.65K Price35.24
SMA20-0.31% SMA50-3.42% SMA20034.86% Trades Volume53,587 Change0.26%
Date Action Analyst Rating Change Price Target Change
Jan-23-24Downgrade JMP Securities Mkt Outperform → Mkt Perform
Mar-16-22Initiated SMBC Nikko Outperform $40
Sep-21-21Initiated JMP Securities Mkt Outperform $46
Apr-26-21Resumed Credit Suisse Outperform $44
Sep-14-20Initiated Evercore ISI Outperform $30
Sep-14-20Initiated Credit Suisse Outperform $26
Feb-28-24 10:25AM
09:15AM
Jan-29-24 11:53PM
Jan-26-24 12:12PM
Jan-24-24 09:46AM
05:58AM Loading…
05:58AM
Jan-23-24 05:05PM
04:42PM
04:02PM
02:45PM
02:30PM
01:23PM
11:25AM
09:40AM
06:02AM
05:39AM Loading…
05:39AM
05:27AM
01:32AM
01:29AM
01:12AM
01:00AM
Nov-09-23 04:00PM
Nov-02-23 09:15AM
Oct-18-23 04:00PM
Sep-19-23 04:00PM
Aug-31-23 10:16PM
Aug-29-23 09:00AM
Aug-07-23 04:00PM
May-30-23 09:00AM
May-08-23 06:05PM
04:05PM Loading…
04:05PM
May-03-23 09:58PM
02:18PM
Apr-26-23 09:00AM
Mar-23-23 07:25AM
Mar-06-23 05:35PM
04:05PM
Jan-30-23 07:33AM
Jan-04-23 09:00AM
Nov-18-22 04:05PM
10:16AM
Nov-16-22 10:42AM
09:00AM
Nov-09-22 06:08AM
Nov-07-22 05:55PM
04:05PM
Oct-20-22 04:05PM
Oct-13-22 06:56AM
Oct-04-22 09:28AM
08:00AM
Oct-03-22 04:30PM
Aug-15-22 04:05PM
Aug-08-22 07:25PM
05:19PM
Jun-30-22 09:00AM
May-19-22 04:05PM
May-16-22 12:32PM
09:00AM
May-09-22 06:35PM
05:25PM
04:05PM
May-05-22 05:15PM
06:18AM
May-03-22 06:32AM
Apr-25-22 09:00AM
Apr-05-22 04:30PM
Mar-24-22 04:05PM
Mar-03-22 09:15AM
Feb-28-22 04:05PM
Feb-22-22 09:00AM
Jan-05-22 07:46AM
Jan-04-22 04:05PM
Dec-20-21 08:50AM
Dec-01-21 04:05PM
Nov-25-21 09:08AM
Nov-24-21 10:31AM
Nov-23-21 10:00AM
Nov-10-21 07:47AM
Nov-09-21 06:45PM
04:05PM
Nov-05-21 03:00PM
Nov-03-21 08:00AM
Nov-01-21 05:51PM
Oct-28-21 08:30AM
Oct-12-21 12:22PM
12:11PM
07:30AM
Oct-11-21 04:05PM
Sep-13-21 04:30PM
Aug-12-21 01:37AM
Aug-09-21 04:38PM
Jun-22-21 06:49AM
Jun-21-21 04:05PM
May-17-21 04:05PM
May-13-21 04:10PM
Mar-14-21 03:21AM
Mar-12-21 09:00AM
Feb-01-21 05:42PM
Jan-13-21 09:00AM
Dec-10-20 06:24PM
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The firm's pipeline is focused on oncology, orphan diseases and infectious diseases. It utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary sdAb platform. The company was founded by Mark Paul Lappe, Quinn Deveraux and Brendan P. Eckelman in April 2010 and is headquartered La Jolla, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
VIKING GLOBAL INVESTORS LP10% OwnerAug 28 '23Buy19.35511,6279,899,982511,627Aug 30 08:44 PM